<SEC-DOCUMENT>0001193125-12-280448.txt : 20120622
<SEC-HEADER>0001193125-12-280448.hdr.sgml : 20120622
<ACCEPTANCE-DATETIME>20120622155059
ACCESSION NUMBER:		0001193125-12-280448
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120618
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120622
DATE AS OF CHANGE:		20120622

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		12922369

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d371198d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported) June 18, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. Pharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City CA </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.
below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;5.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June 18, 2012, the Board of Directors (the &#147;Board&#148;) of the A.P. Pharma, Inc. (the
&#147;Company&#148;) increased the size of the Board from four to six and appointed Barry D. Quart and Stephen R. Davis to the Board. In connection with their appointments to the Board, each of Dr. Quart and Mr. Davis were granted an option to
purchase an aggregate of 5,000,000 shares of Company common stock under the Company&#146;s 2007 Equity Incentive Plan, which options are subject to vesting provisions and continued service during the vesting period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Quart has been president, chief executive officer and a director of Ardea Biosciences, a biopharmaceutical
company, since its founding in December 2006. Previously, he was with Pfizer (NYSE: PFE) as senior vice president, Pfizer Global Research and Development and the director of Pfizer&#146;s La Jolla Laboratories, where he was responsible for
approximately 1,000 employees and an annual budget of almost $300 million. Prior to Pfizer&#146;s acquisition of the Warner-Lambert Company, Dr. Quart was president of research and development at Agouron Pharmaceuticals, Inc., a division of the
Warner-Lambert Company. Dr. Quart had joined Agouron in 1993 and was instrumental in the development and registration of nelfinavir (Viracept<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>), which went from the lab bench to new drug application approval in 38 months. Dr. Quart received his Pharm.D. from University of California, San Francisco.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr. Davis has been executive vice president and chief operating officer of Ardea Biosciences since April 2010. Prior to
joining Ardea, Mr. Davis served as president, chief executive officer and a director of Neurogen Corporation, which was acquired by Ligand Pharmaceuticals (NASDAQ: LGND) in December 2009. Prior to his appointment as chief executive officer of
Neurogen, Mr. Davis served as its executive vice president and chief operating officer and in several other executive roles. While at Neurogen, Mr. Davis completed numerous collaborations with global pharmaceutical companies. Prior to Neurogen, Mr.
Davis practiced as a corporate and securities attorney with Milbank, Tweed, Hadley &amp; McCloy LLP. Previously, he practiced as a Certified Public Accountant with Arthur Andersen &amp; Co. Mr. Davis received his B.S. in Accounting from Southern
Nazarene University and his J.D. from Vanderbilt University. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June
20, 2012, the Company announced that the Company will present patient-satisfaction data from its Phase 3 trial of APF530 at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology (MASCC/ISOO)
International Symposium. The MASCC/ISOO 2012 International Symposium focuses on the clinical management of supportive care in oncology and will be held in New York City June 28 &#150; 30. APF530 is the Company&#146;s lead product candidate being
developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A copy of the
press release announcing the presentation is attached hereto as Exhibit 99.1. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ITEM&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Exhibits. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:23pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated June 20, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: June 22, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:23pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated June 20, 2012</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d371198dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g371198g31u21.jpg" ALT="LOGO">
<B></B><B> </B></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#150; Poster at the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology
International Symposium &#150; </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">REDWOOD CITY, Calif. &#150; June 20, 2012 &#150; <U>A.P. Pharma, Inc.</U> (OTCBB: APPA.OB), a specialty
pharmaceutical company, today announced that the Company will present patient-satisfaction data from its Phase 3 trial of APF530 at the <U>Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology
(MASCC/ISOO) International Symposium</U>. The MASCC/ISOO 2012 International Symposium focuses on the clinical management of supportive care in oncology and will be held in New York City June 28 &#150; 30. APF530 is the Company&#146;s lead product
candidate being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presentation
details are as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patient satisfaction with control of emesis following chemotherapy: comparison of APF530, a subcutaneous extended-release formulation of granisetron versus intravenous
palonosetron</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authors:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rebecca Clark-Snow, Veena Charu, Nashat Gabrail, Ronald Yanagihara,<I> </I>Martin Rosenberg,<I> </I>Erin O&#146;Boyle, John Barr</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Abstract&nbsp;No.:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1109</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presentation:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 29, 2012, Poster Session II</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The full abstract is available on the MASCC/ISOO website, <U>here</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About APF530 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P.
Pharma&#146;s lead product, APF530, is in development for the prevention of both acute-onset and delayed-onset chemotherapy-induced nausea and vomiting (CINV). APF530 contains the 5-HT3 antagonist, granisetron, formulated in the Company&#146;s
proprietary Biochronomer<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> drug delivery system, which allows therapeutic drug levels to be maintained for five
days with a single subcutaneous injection. Intravenous and oral formulations containing granisetron are approved for the prevention of acute-onset CINV, but not delayed-onset CINV. Granisetron was selected because it is widely prescribed by
physicians based on a well-established record of safety and efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> polymer-based drug delivery technology. The Company&#146;s primary focus is on its lead product, APF530, for the
prevention of CINV. A.P. Pharma </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more
-</I> </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B><I>A.P. Pharma to Present APF530 Patient-Satisfaction Data from Phase 3 Study</I><I> </I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page&nbsp;2</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
received a Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA in mid-2012. The Company has additional research and development programs that utilize its
bioerodible, injectable and implantable delivery systems. For further information, please visit the Company&#146;s web site at <U>www.appharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This news release contains &#147;forward-looking
statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties, including uncertainties associated with capital resources and liquidity, timely development and
regulatory approval of product candidates, satisfactory completion of clinical studies, progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company&#146;s filings
with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations
Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Rice </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office
Phone: 646-597-6979 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email: <U>mrice@lifesciadvisors.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact:</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, President and Chief Executive Officer </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">###
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g371198g31u21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g371198g31u21.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+@"5`P$1``(1`0,1`?_$`*(``0`"`P$``P$`````
M```````("08'"@4"`P0+`0$``04!`0$`````````````!P0%!@@)`P$"$```
M!@(!`P,"!`0'`0`````!`@,$!08'"``1$@D3%!4A%C$B,B-"%Q@*05%Q@9$D
M&281``(!`P0!`@0%`0@`!P````$"`Q$$!0`2!@<A,1-!(A0(43)"(Q6!87%2
M8H(S%A?PD;%#)&08_]H`#`,!``(1`Q$`/P#OXXTTXTTXTUY<U-PM;B9&?L4O
M%P$%$-%G\M-33]I%1,6Q;D%1P]D9)\J@S9-$$P$QU%3E(4`ZB(<]H+>>ZG2V
MM4>2YD8*J*"S,Q\`*H!))/@`"IUXW%Q;VD#W-TZ16T:EF=V"JH'J68D``?$D
MT&J)]HO[@;5+#CV0K&#H.=V5M3(RS=27@'B=2Q>W=D+V@4MTE&+Y_/$35']<
M9&NFBI0'L<_4!YMGU_\`9QV5RR)+_DK18+&/0@3@R7)!^(MT(V>/A+)&P^*Z
MUBYS]UG`^-2/9<=23,9!:C=&WMVX(^'O,K%_[XXV0@>'U4+;O[C#=F8DSN*G
M0=?Z9$@8_H1BU8N%I=]@C^3W<J\NT:1=4A?H)DVJ!1'^$.;)X_[&^MH+<+D<
MGF)[KXLK01+_`$3VG(_JYUKYD/O"[$GG+8^SQ<%O\%,<KM_5C-0_T5=;AU__
M`+C_`#+$V:-8;,X?HEOI#EX1*5L.)V\Q5+E",UE"@=\V@YZ>GX&R>R)U$&OK
M1IU0_!;KT`<:YE]C&$?'O/P+*W2994)6*\]MXI&'Z?=B2-HJ^FXK(`?4`>1D
MG$?O%S:7R0<UQ]M+CF>C26P>.1`?U;'=TDI_AK'4?J\:ZRL89,I&9<>T_*F-
MI]G:*+?()C8ZQ.L1-Z#^,?I`HF)TE"D7:NVZ@&2<(*E(LW73.DH4IR&*'.S-
M87)\=RUQ@LU"]OE;29HI8V]5=30C\"/B"*A@002"#K?##Y?'9_%P9K$2K-C;
MF,/&Z^C*?[#Y!'HRD`JP*D`@C6=\M>KEIQIIQIIQIIQIIQIIQIIQIIQIIQII
MQIIQIIQIJ/FSNSV(-1,16#,^:+$2#J\*4K9@Q;@DXL%LL#E-4\95:I%G61-*
MS\H9$WII]Q$TDR'66.D@DHJ3+N#\'Y'V'R*'C'%X#-DIO))\1Q1BF^65_1(T
M!JS'^P`%B`<7YAS#!<%P4O(.0S"*RC%`!Y>1R"5CC7QN=J&@]``68A59AQ0^
M1+;/?O<R/7R#D3$.:,2:F(NTGM+J"-'O$7C,C(RH$B9V[6]S",(RZV!SZA!*
MZ<G*P14/T9HI=PF4ZD=&]=])]:7,>*QN6Q&5[-8%99??A>8/3YX[:'>QB0>1
M\H,KC\[$44<W^X.>]L]@Q/DK_'Y+'\#4AHHQ#,L&VOR22S%%65R:48G:#XC5
M:FM0/T`.H_0`_P"`#FUG_KK6WU_OUO\`KFJ&T5P=0[*JZY9RL#JPUI*YP243
MBRZO/F*BOV>WL\:=*&%)Y`.O5+Z3LAA16$P`0QA$.N`WO:G6>-65K_/XB(03
MF&3==0@I,/6-ANJ'%#5:5%#6E-9=9<`YQD6C2QP^3E:6$2IMMICNB;\LBT3Y
MD/P<54U'GR-:1EX>7KTK)0-@BI."G(=ZXC9>%FF#N*EXJ1:*&1=L)*-?)(/6
M#ULL42J)*D(<A@Z"`#S-+*]L\C:1W^/ECGL9D#1R1L'1U/HRLI*L#\"#36,W
M=I=6%R]G>QR0W<;%71U*NK#P0RL`00?!!`(/KKM'\%^9JKC+QJOK7FK(-<H&
M/JEGV_UR$LU[GX^NUZ-CY<E3D4(U*4F'+9DF5Y;9U]Z9`,'<NJ8``1Z\Y4?=
MIQJ]S/?3X_C%G-=Y:YQ=M*\5NC2R.ZK(&8H@+5$4:$^/R@$^-=*/MDY%:8CI
MKZ[DEU#:8JWR4T:23.L<:HPB8#<Y`\RR/3SY8G5NU7W$U4NV2B8>I^Q&';1D
M]5,3MZ3`W^N2LX\,5H#]1NQ;LGZQ7[Y%D/JJ-T3'733`3&(`%'IK=?=>\[QF
M%_Y'D</DH,%6GOR6\J1#S059E``)\`F@)\`UU/MGSWA61RPP5AE<?-F"*B))
MXV<^*T4!CN8#R5%6`\D`:@'Y$=RLK86VOT2U[Q3D6O8VB\N7&7LV=[!8XNHO
M6+'#]?E(#Y%9:4M[99G6F_PK"=4,\(=`Y!0`0.';R6^G^M<!R?K[EW,L_:3W
M<^+M(H[".)Y`6O9]ZH-D1#2T8Q42A!W'P=1=VOV#FN.<VXUQ;"W<-I!?W#27
MLD@B(6U1X]WS2@A`46?Y@005!KXU8CA/:;7/9!2QHX(S/C[*J]15;IV1M3;"
MSEG40#PRY&3ETV2.#@&#T[90J+DI3-UC)F`AS"`\A_D_!>8\+]C_`)9C+W'_
M`%*EHO?B:/>!2NW<!Y6HW+^85%0*ZECCW,N*\L,R\;R%K>M`0)!$X8K6M"0/
M.TT.UORFAH336`92WZTOPI=1QSE/9?$E,O"2A$GM9E+6R/)Q"I_TISZ3(71*
M\?H/=T?&;B!1`P_0>O+M@>J.RN48PYKC^#R5WB@"1+'`Y1@/78:#W*?Y-VK;
MF>R^`\>O_P"+S.6LK?(`T9&D!9#^$FVOM_Z]NMNY-S]A7#="C<HY/R=3J9CN
M9=PS&&N4M,-@K\P[L;=1W`H1,@V,X1DS3#1(RK;T!4!9,HF+U+]>8YAN+\CY
M%E&PF#LKFZRZ*[-#'&QD41_[A9:54)^K=3;\::O69Y1QWC^+3-YF\@M\3(5"
MRLPV-O!9-K"H;<H+`BH*@GT\ZUO*;N:F0U7R-=Y'/N.DJ=B6V1=$R):49GWD
M!6;G-%3-'5=U+,D7#%U-J^H`';MCK*(G'M4`A@$.7BVZWYY=W]EBK?$WK9/(
MV[3VT7MD230KNK*B&C;/E)#$`$"JU&K9-V#PJ"SNLA)D[46%E.L,\@>J1RMX
M"%Q52U?!"D[:'=2AUB,+Y&=&+%D@<2PNT>(G][*@\7&-3LJ1(L`CH]65?H?=
MBR2=1]^RCVZBBK;W_N"`F<!(!BF`+E<]/]HVF#')+G`Y-,*2H$A@?]3!5.RG
MN49B`K;:&HH:$:M]OVOUO=93^&M\U8/D-I-!(-E%!9J2_P"T2H!J-]10@BHU
MD&$M[-0]C[Y.8RP=GJC9(O->C74Q(05?<2!CJQ3%VW9/9*'?O(]I%V-BS<NT
MBJJQR[HB8*%$P@4P"-+R?JWL/A>+AS7*\1>V&+G<(DDJ;07*E@I%=R,5!(#A
M2:'\#JKX_P!C\'Y5DY,-Q[)6UWDHD+LB%J[00"RDJ%=02/*%AY!]-8]G+R+:
M2ZW6[[!S-L31:C=2%2,\JR/S5HG(D%N@I!/1]0B9]Q7SJD,!RD>@@<Q!`P`)
M1`1K.*].]G\VQ_\`+<6PE[=XRI`E"JB,1Z^VTC()*>A]LM0U'J-47)>U^O.(
M7W\;R#*007]0#&`\K)N\CW!$CF/QY^?;XH?0UU*JBWJG9-I]<R!CZR1%OI5N
MBFLY6K-`O$G\3,Q3TG>W>,G20B4Z9@Z@8!Z&(<!*8`,`@&!Y/&9##9";$Y:&
M2WR5O(T<D4BE71U-"K*?((.LWQ^0L<M8Q9+&RI/83H'CD0U5E/D$'_P0?!\Z
MROE#JLTXTUYTQ+Q=?B92>FW[6*A82.>R\O*/EB-V4;%QK95X_?O'"@@F@U9M
M$3J*',(`4A1$?PYZP037,R6UNK/<2,%55%2S,:*H`\DDD`#XG7C<7$-K`]U<
MNJ6\:%W9C0*J@EF)^``!)/P&N)+(^<MF?+3OVE;<#3D#2\6ZT.'=_P`;3V20
M:)8QQ)CNERS9T[R]D6,E&$M'2,W;W;--RNT5:N%!;`DT$`0:K+%ZD8?B7`?M
MQZ8:QYM!/=\GY'&+>YBMB1=7$LR&EG;NK*R1P!J,X85D)8`LZ(><&7Y+S3OG
MM7ZOBTL5K@,(QFADN*"WMH875C<SAE8%Y&56*E&\;4(*1EQ891,R1SO2KR=9
MLE]Z,F[P,4L3RN.)I*U8]D\?X.KF0+]$S$5'M<25^??.S'9B\M+)$XM&S%H"
M`MQ*F<3E,2"<OQ>Y3M'@W$H.)VG$[ALA%.GMW(N+^6".5&+W<@I1PL3L`U6K
MN]!XU,MAR"-^M^8<@N>1W7(X_HG@;W;=X+2.:96C"V\;L?&YU!V+&H&TA2"M
M.42ET"P7:XT*B,HZ03D,B6JLT^!.NS<HE>O+1,1\(S.T452*5R7UI),W4@F#
MH(#^`\Z5YODF,Q6%R69$\,B8ZUFFE"NK%/:1W(<*25/RD>1Z@^/!UH!BL-?9
M++V>.1&66]N(XXZCPQD957;^/EAZ?CKIDWOVFV;KWDVUSTMU2RE=:?4L4AKS
MCQ&ATQ^+*'GIB4&+FIQ6YL&*?2?A(_'KQD1RV>^JR:,VZR@$()E#CS]ZFZYX
M%=_;_G^U.P;&WN,K>?7RQSS5W1A%,<8A-0%D>ZW[2HW,Q5?0`:W;[+YSS6S[
MGQ'7'`[RX@QUD+*`PQ_D9V"NQF`_.@A:/>KDJJH3XJQ-='F.B3Y1\E>;4\0U
M*5LY@E<78XDW%5A'CUE+Y6+4:O!/(4SQDV,R&Q'EWK6,43.<%3.T^TWYN3Q]
MKF1@XST78/RF\AMT_P#EW4:2R*KI9B1VWA&.[VSLDD4@4VFHU#/W%69Y!W'?
MIQZW:5A);V[M&I8/<^U$A6H\;PQ$97U+K3U.K*=Z==W6!M*/&9XT8Q9NM=LV
M9]K*^1%8]4AAD;*X?)&NBR:R9NY>.97#*B1&JH_J;QZ7^)?I`/5'-CRSM/G?
M?%P"MEBL+</;AJ?(I79;"A\;O9MSN`/YG8>AU-?9?$CQ?KGAW3D+#Z[(Y./W
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M^Y:[M<W;I=X3!8I%V/\`-&TAVL%9/1@'N9*J:J3'0@CQK`_'];<*8:VO\O>Y
MIHV&QQKOA.5#&T5%4F$:L(,6419),K]"L5V-(T8#(S4C2V0M6R())G=RX%#L
M!3J%T[>L^4<DZZZTZR$DV0YEE(6NBTSEY:S[1$))6);8B2/N9JT2*I)VZMO5
M=[QSCW..><^]J.RXICI/IU6%`L9"R,&]N-0%W.T*;0*`M*`*`ZAMNI;['+Z4
MY`SG1]$=7=:L"[4WV,F:W:KC)J7;:_)$U;9T]G1NU13:-?CZ.QE$X95V=N*X
MHMV3A0S4ABN"J'DCJ7%XRT[9L.+9;EF=S7*^.6LBO%`HAQ-JEO&4>WD=VWS!
M"P0NL:[W`#GY:#`.S,C>W775SR7&\<PV)XSG+M&66=C-DIS(_NK-%0$1*P1F
MV5`56)C!#AC+KR&XT?3.,O#=XVUI.2;O;G+XT;W\62PIR<=%TBGU*D2<FB<2
M+$258-[3-+-S'3.5(S,!Z"!1Y'O2?(%L\UV5WE'''2TM;IK<,OR&6[GDEC0@
M&A!,<08?$-ZZS?M;!27&"Z_Z>9I-T\EN)Z'YE6&**%F\C](EF*@BGR^FO;\J
M6N6&</8WT>\?.N%%C:#";(;6UR6LD;$+O7,M/IUUE!49]8K)+OW#R6E9-;[S
M:JG<KJF-U9`(=`(`!2=!<TY/GL]RON;F=Y+>W^!XW,(GDI1'E+-%'$H78BCV
MW"HH`&_TH3JL[NXGQW!8;C?5'$[9+6UR^:C+JA)9Q&J0%Y&8EW/[RDL2?R?"
M@U^'9/5C6[(7ESTFT_I&%,<0.),3X9FLA91J=?JT=&1<Y&IC9YF'A;>9D@FY
ML*!W=<BP.9\HLHM\HH"AC>L?N]N#\]YK@_MTY9V+D<I?R<ARF5AM+::29V=7
MHGNR1%B1&VQY!5-M/;`6FU:>7+^$\2RW?''.#8[&V<>$L,>T]PB1JH8?NNJ2
ME:-)4QQUWEJ^Z2U=QKD.N2N(H+R\>0[8=K`5K'.$M-,$_:3\M/K\?!P46_C(
M2NM+.\"(@VK1FM(%1I$^F"::?J*BF0@`(@'*'FJ\@G^V_A7#'EGO.3<ES,ER
M@E=G=E9W2%0SEOE8SQ-4D"I+?$ZJ>)G`6O?/+.7+'!:<<X]C/;;VHU149$C6
M1MJ`58"&X4`"I\#\-1LV7S[DK)^HNR^X^-=8]/\`6[7K8H\M7UK1DA@6W[3[
M"O9662QFYFZTSBTD:S7)IJNFY>B*@K*,U6;AZ0RYP%TIFO!.$X+!]H8'J[D.
M;Y)F>8X=T?V;1O9Q>.VK]7L=W)EDC\A'**BOO6.H'R#$^<<IS&=X!EN?X;#X
M#%<6RN^+W+E1+D;TL_T^^(*#&C@F1_/E"CR*6/[AZ$/&M0I/&>A.I]0F`[9-
MKA>HS+Q(2]IFRMM:FMWLU"CT$%619T$C]?KW$'KS4/NK,P\@[:Y#EK?_`&),
MK.%_M$;F,'_5LK_76U'4.-EQ/6.#LI_$PQ\3D?@91[NW_3OI_34X.1AJ1].-
M-5'^<#+<QB?QW99)`N%6<ED^7J.(Q>('.15"(N$KZMG2*=,Q1*62JL2]9FZ_
M3M<#S8?[6..6?).[,3%?`-;6GNW>TBH9X(RT7_E+L;_3J"/N1SUS@>I,@UF=
ML]VT=M7\$E:L@_U1*Z'^QCKCKTHWIR+I#.9,>TZE8\R16,P4PM&R#1,E1KY]
M7YR'1,_%L!CQCUBZ(!4I5V@LB<56SINY.11,1`AR=.^W>F\-V]:6"9"\O+#)
M8RX,UO/;E=RLVW=4-X]41E8%61E!!I4'G;UCVIENLKF\>QMK6\L,A![4\,ZE
MD=16GY64^C,"#565B"I\$;&R_P"3C+V6]:;?J<AB?7S$V'+7:X:R(P6&*`[H
M(0#2!?Q$JRKS!%G.N&,DS7DX9-PZ=R"3N1<JF'N7[0(4F-<4^W/C7%N>6O8K
M97,Y'D5M`Z%KR99S([H\9E9R@=2%<A$4A%`'CU)OG(N].1\@XG<<*2QQ-CQZ
M>=)!':VYAV!&5P@I(0074,S.K.S>KTH!++5';>R[M;S:"1>>UL18JQ=J)%R#
MBLBQ=*U"KM8VC5AH_@EIE]<K-(-EYMY.52$;)@FJB40)^5/]0\C;L;JNQZCZ
MDY=/PXY/)9_DLL22[D$TO[LS&0*((U;9LDF9F(:I(KK/.`=B778_97%X>6'&
MV&#P*'VR#[$:B&,-'N,LK*6+PQ**%?3P-?7G'S3YV2R]G5]BK'^N3.S/;]D*
MIXUV10Q-%OL[1.*PGI*'JD-'7`COX^5!*`31*V<.&;@3$,7N*J(`;CAOVG<3
MFXUAYN39#-?0BRMY[K&FY*637119)69"`T8W$AP"K"AHR^FO3E/W)<D'(LF>
M/V6(_D&N9X;;("V5KQ;;<RQ*LN[:Q"4H2C#\:^NKZ?"]@+8C'6K2@[.0,#&-
MKOD1_F>G5>?AI1QEA6PV)\2:>9$RO+R\LZ2&S2;M%LK'L_9HO6";<BSE07)P
M30U`^YSE/!<[V&6X!)+)!:VB6<DB,@M-D*>VL%FB(I]E%W!G+LLC,P0!`&?:
M3[=N-<PQ7"#_`,WBB0W-V;J*-T8W)=R&,]RS.W[C$*478KH%#.=QHNBMU-:)
MC>3RSX6Q3?:7E)MKGB'7JQRM@R#7V=FK,0E=IY*>E&'VSD)!@$0VLT?,N:XL
M0B2RBG<R.4Y#%*<O,LZPYW;]5_;YE\[AKNP/-\IFH(DMY#'*YM8@N\RVS$DQ
M.OOH2R@4?P02IUC78W#+CLOO/&X3*07B\2QV,>1YHP\8$S"1E,<VW;O#FW-`
M6J4(*D!AJQ34_P`:>O6I5XG\M0,CDK+6:+%'GAG67LY7`;[>(^#4`A%8B#>C
M'QC.+;ND$DTUEBHF=JI$!,5O1$4^0WS_`+JYCV%BX./WJ6./XQ;O[BV5A`+:
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M6#*J1-2<.Q*JNU:QR*BQTR]RO:':.83_`'2=J/=7=U9-B[+Z^)TG6WL88Q*9
M!0RN]&E:4"H#M(:5-!4UUB4'VU];I;6UO=_R-TUJX,;37+,54?\`M!`JQ".M
M"0L8;P/FU.FZZ=89R#M!BS;JU-[-(99PW5Y"J4)+Y]5*GQ;&32LJ+IZM6B-_
M1=RQBVIR)5SJ=2F*D/3JD7D6XSL/DN(X-D.O+%X4XYD[B.:X'MJ96:(H4`E_
M,$!C7Y1X_-_B-9,R/`>/Y7F5ESJ]$S9S'PF.'YS[2AA*"3'2A;]UO-?@AI\H
MI]F3-/<+Y=V$PQLS>&5CDLE8#;/V^-TT;$\:U:-5DCO%',@]KJ1?:R,CZCL#
M%5.;J4R"(]/VPY\PO8?)N/\`$,GPC%R11X/+LANOVU,CB,@HHD/S*HIY4>NY
MJ^NOWE^"\?SG)[#EN221\MC01!\Y$:DDDL4I0M4^M?TK^`U\Z[J!A>L[2WK<
M9E'V!UF_(%,94&8EI.Q/GL&PK+!M6VJ;*!KQ^UA$J*I55KZBA`$YA]0>H>J?
MK\O.PN37O!+3KB62(<5L[MKE$6-5<S/OJTD@&]_$C`!C0#:!^44_-IP/CUGS
M2YY_&DIY'=6XA9FD)01@1"B)Z+XA3R/\Q_4U<5QQH1K9C&,V6B(>JR\S'[<R
MLY*YV1M=FEYT]L4L1+$24:(N%ETG,.Q5"U/A(1J=,R1E^XABF*40KLSVIS/.
M2X.>ZN$CDX[%''8&*-(_9$3(R&@%&8-&A)8&M/-=46)ZRXCB(<Q!!`\D6==V
MO!([-[ON>YN%?!4'W7]#45]?`I$AAX+?'>VJ[RJR./L@61FL[*YC'M@RY>W4
MA6$1<&<NH^K^UEF4?#,Y-4P>[$C<5W0%`%%#<D:?[JNYY<E_*0W]M!<E-LGM
M6EL@F^7:&F_;+2,H_)N:B?I`U@\/VV]3QV9LI;*>:,-52]Q-6,%MQ6,*RJH)
M\GY2QH*G5N,/$L(&)BX.+0*UC(:.8Q,<V*(B5NPCFR3-F@41^HE1;HE*'^G-
M>)I9)Y6GE):5V+,?Q)-2?ZG4YP016T"6T(I#&@51^"J*`?T`UZ///7KIQIJO
M[R=ZIS>X^F^3,04\6PY!;GAKUCI%XNFU:/[A3'H2;2$7=+"5%I]QQHNHXBRA
MBIHJ.RJ'$"%-R7.C.P;;K+LW'<IOPQQ*L\5QM%6$,RE'=1ZDQDB2@\MMVCR=
M19W-P>X["Z]O>/6-/Y2BRP5(`,L1J$J:`>XNZ,$D!2P)-`=?SP;94[10[--T
MN[UV:J%OK;]>+L%8L<<ZB)V&D&QQ37:2$:]32<MU2&#Z=2]IRB!BB)1`1[:X
MG+8O/8Z++X2XAN\9.@9)8F#HP/D$$$_U!\@^"`=<A\GBLCAKZ7&Y6&2WOH7*
MNCJ596'P((!&L>,8I0ZF,!0#\1,(``?[C].7&AU0@%C114ZE=K;H[M)MS+-H
MW!^'K-:(E5P5%Y>)-F>OXXAPZCWK2=VF$V\'W(E*)A0;'<O#@`@FB<?IR+^>
M]S=<]:P-)R?)PI?*/%M$1+<N?@!"A++7Q\TFQ!7RPU(G"NK.><[N%3CEA.]N
M3YG8>W"HK0DRM1?%#\H)8T\*3XUUT>/#PE8?U-?0>6,UOHK-^>X[T7T0HHP.
M&-,;R1!`Y'-0A9$@.)Z?9F#]N8D4R'2,`';-FJ@=YN;'=/W3\K[,CEX_Q]7Q
M/#7J&C5JW%RO_P!B1?1#\88SM/H[2#6__4GVV\<X`\>:S[)DN4+Y5BO[$#>M
M8D;R[CX2.!3P51&%3>5S536RVG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&FG&
MFG&FG&FH);=_^<WJ1W]:G]+GROI)?$?SF^P_N[VGY_3^*^6_^I^/Z]>OH_L_
MY\E#KW_N#>__`%C_`#U-WS_0_4>WNI^OVOV]U/\`%YIZ:C3G7_4VY/\`L/\`
MA?J/T?5^Q[M/\N_]RG]WC\=1@Q3_`.&7W4T_EE_0/]U]Q?CO7_EC[OU_X/C?
MN?\`9]WU_3Z/[O=TZ?7IS.N1_P#ZE_CS_P`C_P"8_P`=0[MWUFRGQW;?TT]=
MWBGKK#<+_P#FWZ]?XC_B_P#(?IK]/6OC\ON>*^E*>?PU;U#_`!'Q;#X#XWX7
MVJ7QGP_M?B_9]H>A[#V7_4]KV?I]/\G3\.:]3>][S?4;O?W'=NKNK\=U?-:^
MM?.IX@]CV4^FV?3[1MVTV[?AMIXI3TIXUZ7/+7KIQIIQIIQIIQIIQIIQIIQI
0IQIIQIIQIIQIIQIIQIK_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
